Skip to main content
    S

    Structure Therapeutics Inc. American Depositary Shares (GPCR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.57
    -1.43 (-7.15%)

    Market Cap: $1.43B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Structure Therapeutics Inc. American Depositary Shares (GPCR) to earn -$2.22 per share in the fiscal year ending Dec 31, 2026. Of 16 analysts, 15 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 1.81, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.

    RatingAnalystsShare
    Strong Buy425.0%
    Buy1168.8%
    Hold16.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    16

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$2.22
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$2.73
    EPS consensus, revenue $62500
    Fiscal year ending Dec 31, 2028
    -$1.61
    EPS consensus, revenue $186.40M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.22-$2.26 to -$2.086N/AN/A11
    Dec 31, 2027-$2.73-$3.21 to -$2.228$62500N/A8
    Dec 31, 2028-$1.61-$2.43 to $1.098$186.40M$186.40M to $186.40M10

    Quarterly Estimates

    The EPS consensus falls from -$0.60 for the quarter ending Dec 31, 2026 to -$0.67 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.60-$1.24 to -$0.3417
    Mar 31, 2027-$0.67-$0.71 to -$0.556

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 4 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202602
    Fiscal year ending Dec 31, 202712
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.62.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.22-$1.62-$1.62-$1.64-$1.62N/A
    Fiscal year ending Dec 31, 2027-$2.73-$2.19-$2.19-$2.18-$2.19N/A
    Quarter ending Mar 31, 2027-$0.67-$0.53-$0.53-$0.53-$0.54N/A

    Frequently Asked Questions About GPCR

    What is the GPCR stock forecast?

    Consensus analyst estimates put Structure Therapeutics Inc. American Depositary Shares's EPS at -$2.22 for the fiscal year ending Dec 31, 2026. The consensus rating from 16 analysts is Buy.

    How do analysts rate GPCR stock?

    Of 16 analysts covering Structure Therapeutics Inc. American Depositary Shares, 4 rate it Strong Buy, 11 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from GPCR next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.22, with estimates from -$2.26 to -$2.08 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.73, with estimates from -$3.21 to -$2.22 from 8 analysts.

    What revenue do analysts expect from Structure Therapeutics Inc. American Depositary Shares next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $62500. For the fiscal year ending Dec 31, 2028, the consensus revenue estimate is $186.40M, with estimates from $186.40M to $186.40M.

    How many analysts cover GPCR?

    16 analysts rate Structure Therapeutics Inc. American Depositary Shares stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.